1. PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer 
Mathilde Guerin, Keyvan Rezai, Nicolas Isambert, Mario Campone, Aurélie Autret, Jihane Pakradouni, Magali Provansal, Jacques Camerlo, Renaud Sabatier, François Bertucci, Emmanuelle Charafe-Jauffret, Alice Hervieu, Jean-Marc Extra, Patrice Viens, François Lokiec, Jean-Marie Boher, Anthony Gonçalves 
European Journal of Cancer 
Volume 86, Pages (November 2017)
DOI: /j.ejca
Copyright © 2017 Elsevier Ltd Terms and Conditions

2. Fig. 1 Dose escalation schedule.
European Journal of Cancer  , 28-36DOI: ( /j.ejca )
Copyright © 2017 Elsevier Ltd Terms and Conditions

3. Fig. 2
Complete response after two cycles of buparlisib 80 mg–lapatinib 1250 mg. A 45-year-old women with HER2-positive, oestrogen receptor–positive inflammatory breast cancer with second metastatic relapse (ovarian and retroperitoneal relapse) was enrolled in PIKHER2 study on November 2014 (left panel) and received buparlisib 80 mg plus lapatinib 1250 mg once daily. After two cycles (right panel), she reached complete remission. Arrow indicates initial metastatic lymph nodes (left panel) and their disappearance (right panel).
European Journal of Cancer  , 28-36DOI: ( /j.ejca )
Copyright © 2017 Elsevier Ltd Terms and Conditions

4. Fig. 3
Clinical benefit rate according to PIK3CA genotype and hormone receptor expression. (A) Clinical benefit rate (objective response and/or stable disease for at least 24 weeks) according to PIK3CA mutational status, as determined by Sanger sequencing on archival or freshly obtained metastatic tissue. (B) Clinical benefit rate according to expression of hormone receptors on metastatic tissue.
European Journal of Cancer  , 28-36DOI: ( /j.ejca )
Copyright © 2017 Elsevier Ltd Terms and Conditions